Tempus AI reported strong financial results for the first quarter ended March 31, 2025, with total net revenue reaching $255.737 million, a substantial 75.4% increase year-over-year. Gross profit nearly doubled, climbing 99.8% to $155.203 million.
The company reported a net loss of $(68.037 million) for the quarter. Adjusted EBITDA improved significantly to $(16.174 million), representing a 63.2% improvement year-over-year, demonstrating strong operational leverage.
Tempus raised its full-year 2025 revenue guidance to approximately $1.25 billion for the consolidated Tempus and Ambry Genetics business, representing approximately 80% annual growth. The company reaffirmed its expectation of achieving adjusted EBITDA positive status for the full year 2025, targeting around $5 million, an improvement of approximately $110 million over 2024.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.